Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at everolimus and dovitinib for kidney cancer that has spread (DEVELOP)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
More about this trial
Everolimus is a type of biological therapy called an mTOR inhibitor. It stops a protein called mTOR from working properly. mTOR controls other proteins that trigger cancer cells to grow. By blocking mTOR, everolimus may help stop cancer growing.
Doctors often use everolimus to treat kidney cancer that has spread. But it doesn’t always work. Doctors want to find out if taking a drug called dovitinib at the same time will help it work better.
Dovitinib is a new drug and is a type of biological therapy called a tyrosine kinase inhibitor or TKI. TKIs block tyrosine kinase, which is a chemical messenger (an enzyme) that sends messages to tell cells to divide and grow. Blocking tyrosine kinase may stop cancer cells growing.
The aims of this trial were to find out
- The best dose of everolimus and dovitinib to use for clear cell kidney cancer that has spread
- More about the side effects
- How well this new combination of treatment works
Summary of results
Despite attempting to contact the trial team, we have not been able to have the results for this trial checked.
How to join a clinical trial
Prof Thomas Powles
Experimental Cancer Medicine Centre (ECMC)
Queen Mary University of London